Key result
Ivabradine is recommended as an adjunct therapy to reduce heart failure hospitalization or cardiovascular death in symptomatic patients with reduced ejection fraction and a resting heart rate of at least 70 bpm.
Ivabradine is an established adjunctive therapy that reduces heart failure hospitalizations and cardiovascular death in patients with HFrEF who remain in sinus rhythm with a heart rate ≥70 bpm despite maximally tolerated guideline-directed medical therapy.
Supports ivabradine in HFrEF with HR ≥70 bpm on optimal therapy; leaves open role amid evolving GDMT.
Heart failure represents a major global cause of morbidity and mortality. Ivabradine is a selective funny current (I f ) inhibitor, which acts on the sinoatrial node, resulting in a reduction in heart rate. Ivabradine is currently licensed for use in patients with symptomatic heart failure with reduced ejection fraction and a heart rate persistently at least 70 beats per minute in spite of otherwise optimal prognostic heart failure pharmacotherapy. In this review article, we examine the mechanism of action of ivabradine, evaluate the clinical trials underpinning its application in heart failure and discuss its current recommended clinical use in this capacity.
No takes yet. Share an insight, caveat, or question.
Badu-Boateng et al. (2018) conducted a review in Heart failure. Ivabradine was evaluated. Ivabradine is recommended as an adjunct therapy to reduce heart failure hospitalization or cardiovascular death in symptomatic patients with reduced ejection fraction and a resting heart rate of at least 70 bpm.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: